Key result
Review compares dobutamine versus milrinone for pharmacological support in HFpEF with low cardiac output syndrome.
Why the study?
Does dobutamine improve outcomes compared to milrinone in patients with decompensated heart failure and low cardiac output?
Does dobutamine improve outcomes compared to milrinone in patients with decompensated heart failure and low cardiac output?
Answers are grounded in this paper and cite their sources.
The choice between dobutamine and milrinone in decompensated heart failure should be individualized based on hemodynamic profile and side effect tolerance, as neither has proven superior efficacy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Marcely Gimenes Bonatto (2022) conducted a review in Heart Failure with Preserved Ejection Fraction. Dobutamine vs. Milrinone was evaluated. This review discusses the choice between dobutamine and milrinone as pharmacological support for patients with heart failure with preserved ejection fraction and low cardiac output syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: